Latest news for Conavi Medical (OTC:CNVIF) Stock

Conavi Medical Corp is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its Novasight Hybrid System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries.

Conavi Medical Corp

References to "30+ delinquency rate" are to over-30 day loan delinquencies as a percentage of period-end loan receivables.&nbsp;

News

Synchrony Financial October 30+ Delinquency Rate 4.9% Vs. 4.6% Last Year; Net Charge-off Rate 6.2% Vs. 5.4% Prior Year - Filing

Digihost Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGHI#NASDAQ">DGHI</a>) reported quarterly sales of $9.200 million which missed the analyst consensus estimate of $9.900 million by 7.07 percent. This is a 71.74 percent increase over sales of $5.357 million the same period last year.

Earnings

Earnings Misses

DGHI

Digihost Technology Q3 Sales $9.200M Miss $9.900M Estimate

The termination of Walmart program agreement, effective May 21, 2024, increased the Domestic Card net charge-off rate by 39 basis points for October 2024. Excluding this impact, the Domestic Card net charge-off rate would have been 5.43%

Capital One Financial October Credit Card Domestic 30+ Day Performing Delinquencies Rate 4.61%, Net Charge-Offs Rate 5.82% - Filing

Redburn Atlantic analyst Simon Baker upgrades Autolus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUTL#NASDAQ">AUTL</a>) from Neutral to Buy and announces $13 price target.

Upgrades

Price Target

Analyst Ratings

AUTL

Redburn Atlantic Upgrades Autolus Therapeutics to Buy, Announces $13 Price Target

ALHC

Alignment Healthcare Enters Into Privately Negotiated Subscription Agreements With Certain Investors, Pursuant To Which It Will Issue $330M Principal Amount Of 4.25% Convertible Senior Notes Due 2029

AMPG

Amplitech Group Reports Q3 Revenues Of $2.834M, Exits Quarter With Cash & Equivalents Worth $2.352M

Redburn Atlantic analyst Harry Read initiates coverage on Insight Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSIT#NASDAQ">NSIT</a>) with a Buy rating and announces Price Target of $220.

Initiation

NSIT

Redburn Atlantic Initiates Coverage On Insight Enterprises with Buy Rating, Announces Price Target of $220

SMXT

SolarMax Technology Q3 EPS $(0.21) Down From $0.04 YoY, Sales $6.3M Down From $14.3M YoY

AUPH

Aurinia Presents Data Underscoring Critical Importance Of Earlier Lupus Nephritis Detection And Intervention And Value Of LUPKYNIS, A Second Generation Calcineurin Inhibitor

Redburn Atlantic analyst Harry Read initiates coverage on CDW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>) with a Buy rating and announces Price Target of $230.

Redburn Atlantic Initiates Coverage On CDW with Buy Rating, Announces Price Target of $230

Sigma Lithium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGML#NASDAQ">SGML</a>) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $0.12 by 358.33 percent. The company reported quarterly sales of $20.894 million which missed the analyst consensus estimate of $72.779 million by 71.29 percent. This is a 78.46 percent decrease over sales of $97.000 million the same period last year.

SGML

Sigma Lithium Q3 2024 GAAP EPS $(0.31) Misses $0.12 Estimate, Sales $20.894M Miss $72.779M Estimate

Wolfe Research analyst Alexandria Hammond initiates coverage on Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Outperform rating and announces Price Target of $1150.

REGN

Wolfe Research Initiates Coverage On Regeneron Pharmaceuticals with Outperform Rating, Announces Price Target of $1150

In the wake of Donald Trump&#8217;s recent election victory, companies are rushing to tap into the US bond market, taking advantage of favorable conditions. Firms such as Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>), Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), and Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) have collectively raised over $50 billion in the past week.
What Happened: The surge in corporate borrowing is driven by a rally in credit and equity markets, which has pushed borrowing costs to historic lows. Investors are optimistic about potential tax cuts boosting profits, leading to a decrease in corporate borrowing costs relative to U.S. Treasuries, <a href="https://www.ft.com/content/5f9eb247-2851-4da7-ac19-62761fb46d1d">reported</a> The Financial Times on Friday. The U.S. investment-grade bond spreads were at 0.8 percentage points late Thursday, nearing their lowest since 1998.
Banks have been quick to capitalize on these conditions, with significant activity in the financial sector. 
See Also: <a href="https://www.benzinga.com/news/24/11/41963694/amid-appointment-of-elon-musk-vivek-ramswamy-team-trump-now-reportedly-planning-to-overhaul-military-posts?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Amid Appointment Of Elon Musk, Vivek Ramaswamy, Team Trump Now Reportedly Planning To Overhaul Military Posts</a>
Why It Matters: The bond market has been experiencing heightened volatility, as evidenced by <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41746843/bond-market-fear-gauge-soars-to-1-year-high-ahead-of-us-election-results-bond-vigil">the MOVE index</a> reaching its highest level in over a year ahead of the U.S. election. 
Following Trump&#8217;s election, bond yields have <a href="https://www.benzinga.com/markets/bonds/24/11/41887642/bond-etfs-slide-as-fed-cuts-clash-with-trumps-fiscal-agenda">continued to rise</a>, complicating the Federal Reserve&#8217;s efforts to ease borrowing costs. The 10-year Treasury yield reached 4.34%, influenced by speculation surrounding Trump&#8217;s fiscal agenda.
Trump&#8217;s reelection has had a profound impact on financial markets, with the <a href="https://www.benzinga.com/trading-ideas/24/11/41977313/will-trumps-election-win-push-sp-500-even-higher-in-final-weeks-of-2024-over-75-say">S&amp;P 500 Index</a> reaching new all-time highs since the election. This contrasts the volatility experienced by the emerging <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41984852/trumps-red-wave-pushes-emerging-market-stocks-to-2-month-lows-volatility-expected-to-remain-elevated">market stocks dropping</a> to levels last seen in mid-September.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41910180/exclusive-chris-christie-says-trump-will-remove-federal-restrictions-on-marijuana-find-sweet-spot-for-crypto-regulation?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Chris Christie Says Trump Will Remove Federal Restrictions On Marijuana, Find &#8216;Sweet Spot&#8217; For&nbsp;Crypto Regulation (UPDATED)</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Bonds

Markets

General

GILD

Trump's Victory Spurs $50B Corporate Bond Surge As Tax Cut Optimism Drives Borrowing Costs To 25-Year Low

Wolfe Research analyst Alexandria Hammond initiates coverage on Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) with a Underperform rating and announces Price Target of $25.

Wolfe Research Initiates Coverage On Pfizer with Underperform Rating, Announces Price Target of $25

<a href="https://www.bostonfed.org/news-and-events/events/economic-research-conference-series/the-future-of-finance.aspx" title="https://www.bostonfed.org/news-and-events/events/economic-research-conference-series/the-future-of-finance.aspx">https://www.bostonfed.org/news-and-events/events/economic-research-conference-series/the-future-of-finance.aspx</a>

Federal Reserve

Fed's Collins To Speak At Federal Reserve Bank of Boston Event At 9AM ET Today

Wolfe Research analyst Alexandria Hammond initiates coverage on Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Underperform rating and announces Price Target of $40.

MRNA

Wolfe Research Initiates Coverage On Moderna with Underperform Rating, Announces Price Target of $40

Fed's Collins Said Doesn't See Signs of New Price Pressures

Fed's Collins Said Fed Policy Is Restrictive; Expects Lower Rates Will Be Warranted

Wolfe Research analyst Alexandria Hammond initiates coverage on Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Peer Perform rating.

Comments

Conavi Medical

News

Latest news for Conavi Medical (OTC:CNVIF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga